been awarded 4 out of 4 highly competitive grants: (1) CIRM, (2) SBIR-NIH, (3) SBIR-NCI, and (4) NYSTEM—the latter, $15.8M awarded to Cornell while Angiocrine retains full commercial rights. Other highlights: • Signed a 3-year Corporate Agreement with TerumoBCT, a division of Terumo Corporation (publicl

be fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

be fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

e fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < > wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

e fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < > wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

30 +0000 Attachments: Angiocrine_Bioscience_Confidential_NUMBERS_deck_Jun_2015_v 150701.pptx Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

e fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < > wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

pe this email finds all is well with you and your family. It's been about a year-and-a-half since we met at your residence in Manhattan. Since then Angiocrine team and programs have progressed forward. We moved the company to San Diego. We were awarded a $3.8M non-dilutive grant from CIRM, the State of Cal

be fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the serie

to meeting you </=iv> On Thu, Jul 2= 2015 at 4:41 PM, Jeffrey Port < <mailto » wrote:=br> Jeff Hope all well Wanted=to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a=50 million pre money valuation. We=are offering a 25% discount to the serie